Cargando…

Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period

BACKGROUND: Interleukin-23 inhibitors are novel treatment options for psoriasis, and their efficacy and safety have been widely demonstrated in phase 3 clinical trials. Nonetheless, their real-world data remain limited, especially in Asia. OBJECTIVE: To evaluate the real-world effectiveness of inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Yung, Tong, Bik Sai Bessie, Ngan, Pui Yan, Au, Chi Sum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179803/ https://www.ncbi.nlm.nih.gov/pubmed/34104632 http://dx.doi.org/10.2147/PTT.S312109

Ejemplares similares

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

Guselkumab for plaque psoriasis
Publicado: (2019)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab
por: Stryckers, Marijke, et al.
Publicado: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China
por: Yang, Jing, et al.
Publicado: (2022)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient
por: Kim, Sa Rang, et al.
Publicado: (2019)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
por: Chiang, Cheng-Ying, et al.
Publicado: (2021)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study
por: Sano, Shigetoshi, et al.
Publicado: (2018)

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis
por: Nam, Hyun Min, et al.
Publicado: (2021)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
por: Eyerich, Kilian, et al.
Publicado: (2021)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
por: Hung, Yi-Teng, et al.
Publicado: (2021)

The role of IL-23 in the immunopathogenesis of psoriasis
por: Meglio, Paola Di, et al.
Publicado: (2010)

Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
por: Haberman, Rebecca H, et al.
Publicado: (2022)

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
por: Wechter, Todd, et al.
Publicado: (2018)

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
por: Song, Eingun James, et al.
Publicado: (2020)

Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study
por: Ghislain, Pierre-Dominique, et al.
Publicado: (2021)

Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies
por: Fu, Hongyi, et al.
Publicado: (2022)

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
por: Hugo, Jan, et al.
Publicado: (2023)

Correction: Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
Publicado: (2023)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

Guselkumab‐associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature
por: Burlando, Martina, et al.
Publicado: (2021)

Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
por: Campbell, Kim, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pf7iml681u5mhmatqu7t8g35cs